Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as Alcobra Ltd, is based in San Diego, CA.
| Revenue (Most Recent Fiscal Year) | $82.03M |
| Net Income (Most Recent Fiscal Year) | $-65.78M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 3.97 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.14 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -143.80% |
| Net Margin (Trailing 12 Months) | -143.80% |
| Return on Equity (Trailing 12 Months) | -36.55% |
| Return on Assets (Trailing 12 Months) | -28.40% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.31 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.31 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $7.53 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.95 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.40 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.81 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 28.42M |
| Free Float | 23.36M |
| Market Capitalization | $217.44M |
| Average Volume (Last 20 Days) | 0.45M |
| Beta (Past 60 Months) | 2.36 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 17.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 94.54% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |